Ranolazine ELC 750 mg
As listed in the register: Ranolazine ELC 750 mg, tabletten met verlengde afgifte
750 mg · tablet met verlengde afgifte
- Prescription only
- Heart, blood pressure and circulation
- Active substance
- Ranolazine
- Made by
- ELC Group s.r.o.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Ranolazine). It describes the substance, not this exact product.
The mechanism of action of ranolazine’s antianginal effects has not been determined.
Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure.
Ranolazine is extensively metabolized in the gut and liver and its absorption is highly variable.
Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces.
The pharmacokinetics of ranolazine is unaffected by age, gender, or food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-19
Safety of the active substance
From the US prescribing label for the same active substance (Ranolazine). It describes the substance, not this exact product.
- Ranolazine extended-release tablets are contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1) ] Taking inducers of CYP3A [see Drug Interactions (7.1) ] With liver cirrhosis [see Use in Specific Populations (8.6) ] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) CYP3A inducers (e.g., rifampin, phenobarbital, St.
- John’s wort) (4, 7.1) Liver cirrhosis (4, 8.6)
Most common adverse reactions (greater than 4% and more common than with placebo) are dizziness, headache, constipation, nausea.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
Spain18 matching products
- RANEXA 750 mg · comprimido de liberación prolongada6 makers
- LABIGAT 750 mg · comprimido de liberación prolongada
- RANOLAZINA ALTER 750 MG · comprimido de liberación prolongada
- RANOLAZINA AUROVITAS 750 mg · comprimido de liberación prolongada
- RANOLAZINA CINFA 750 mg · comprimido de liberación prolongada
- RANOLAZINA INTAS 750 MG · comprimido de liberación prolongada
- RANOLAZINA KRKA 750 MG · comprimido de liberación prolongada
- RANOLAZINA NORMON 750 mg · comprimido de liberación prolongada
FranceNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | ELC Group s.r.o. |
|---|---|
| Active substance | Ranolazine |
| Used in | Heart, blood pressure and circulation |
| Strength | 750 mg |
| Form | tablet met verlengde afgifte |
| Classification | C01EB18 · Heart, blood pressure and circulation |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Ranolazine ELC 750 mg, tabletten met verlengde afgifte |
| RVG | 127792 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.